In this review, we highlight recent clinical trial data reported in the literature dealing with different ways to target various carcinogens in gastric cancer. Moreover, we touch upon other multidisciplinary ..... see more
Conclusions: In this review, we highlight recent clinical trial data reported in the literature dealing with different ways to target various carcinogens in gastric cancer. Moreover, we touch upon other multidisciplinary therapeutic approaches such as surgery, adjuvant and neoadjuvant chemotherapy. Rational clinical trials focusing on...
We present an unusual case of laparoscopic total gastrectomy with lymph node dissection in a 56-year-old woman with gastric cancer and agenesis of the dorsal pancreas (ADP). Esophagogastroduodenoscopy revealed erosive ..... see more
Background Some reports showed the immune tolerance of soluble human leukocyte antigen E (HLA-E), but the role that soluble HLA-E plays in gastric cancer (GC) is unknown. We aimed to ..... see more
Background Gastric cancer (GC) is one of the leading causes of cancer-related death worldwide. The first-line treatment for GC is a combination of platinum and fluoropyrimidine-based therapy. Based on the ..... see more
Conclusion: Treatment with ramucirumab plus paclitaxel yielded the highest overall response rate reported to date for patients with previously treated advanced GC. In our experience, the initial tumor response is associated with a greater survival benefit which could be further improved by the identification of biomarkers predicting response.
1 Third Department of Internal Medicine, University of Toyama, Toyama, Japan. 2 Third Department of Internal Medicine, University of Toyama, Toyama, Japan; [email protected] 3 Department of Clinical Oncology, University of ..... see more
The purpose of this study was to investigate the impact of a family history of malignant tumor on the prognosis of patients with gastric cancer and develop a nomogram that ..... see more
Purpose Defining the phenotypic characteristics of CD8+ T cell subsets in gastric cancer (GC) can help remodel the immune microenvironment of the tumor, thereby improving patient prognosis. CD226 has recently ..... see more
Typically, early-onset gastric cancers (EOGC) present at the age of 45 years old or younger. Although its prevalence ranges from 2.7% to 15% depending on the population being studied, it ..... see more
Conclusions: As explained above EOGC is a growing health concern that affects young individuals. Furthermore, the reported case displayed a poor response to standard therapy including checkpoint inhibitors and chemotherapy despite the presence of biomarkers that predict a favorable outcome. Future studies should adopt alternative approaches to...
PURPOSE: Frailty predicts poor outcomes in older adults with cancer, but how it differs between different cancer types is unknown. We examined differences in pretreatment frailty between colorectal (CRC), pancreatic, ..... see more
Comparing Different Anesthesia Methods on Anesthetic Effect and Postoperative Pain in Patients with Early Gastric Cancer during Endoscopic Submucosal Dissection: Endoscopic submucosal dissection (ESD) is a minimally invasive technique to ..... see more
Conclusion: Compared with simple intravenous general anesthesia, intravenous combined inhalation general anesthesia can better maintain the intraoperative hemodynamic stability of patients with early gastric cancer, shorten the postoperative recovery time, and reduce the postoperative pain. On the other hand, this study is a retrospective...
BackgroundThe mean age of gastric cancer (GC) patients has increased due to the aging society. Elderly GC patients with poor physical status tend to develop complications during the treatment courses, ..... see more
Gut Microbiota Dysbiosis in the Development and Progression of Gastric Cancer: Objectives . This study aims to explore gut microbiota dysbiosis in the histological stages of gastric cancer (GC). Methods ..... see more
Gastric carcinoma and gastro-oesophageal junction (GC/GEJ) carcinoma remain a significant global problem, with patients presenting with symptoms often found to have advanced or metastatic disease. Treatment options for these patients ..... see more
Conclusion/Relevance: In this review, we highlight the positive evidence from key trials that have led to our current practice algorithm, with particular focus on the refractory advanced disease setting, discussing the areas of active research and highlighting the factors, including biomarkers and the influence of ethnicity, that contribute to...
Gastric cancer remains an enormous threat to human health. It is extremely significant to make a clear diagnosis and timely treatment of gastrointestinal tumors. The traditional diagnosis method (endoscope, surgery, ..... see more
Conclusion/Relevance: This work aims to construct a cheap, non-invasive, rapid, and high-precision gastric cancer diagnostic model using personal behavioral lifestyles and non-invasive characteristics. A retrospective study was implemented on 3,630 participants. The developed models (extreme gradient boosting, decision tree, random forest, and...
Microsatellite instability (MSI) status is an important prognostic marker for various cancers. Furthermore, because immune checkpoint inhibitors are much more effective in tumors with high level of MSI (MSI-H), MSI ..... see more
Gastric cancer (GC) is one of the most prevalent malignancies of the digestive tract. Ginsenoside Rh1 was reported to exert effects on GC. The current study set out to explore ..... see more
Background Recurrence after curative-intent surgery can occur in more than 50% of gastric cancer (GC) patients. We sought to identify predictors of very early recurrence (VER) among GC patients who ..... see more
1 Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville. 2 Center for Drug Evaluation and Safety, University of Florida, Gainesville. 3 College of Medicine, University ..... see more
Compared to standard chemotherapy, the use of Nivolumab in patients with advanced esophageal, gastroesophageal, and gastric cancers is associated with improved overall and progression-free survival, with similar rates of AE ..... see more
Conclusions: Compared to standard chemotherapy, the use of Nivolumab in patients with advanced esophageal, gastroesophageal, and gastric cancers is associated with improved overall and progression-free survival, with similar rates of AE and AE leading to death. The improvement in survival was significant in patients with ≥1% PD L1 expression.